Commentary on "the risky business of studying prognosis"

Research output: Contribution to journalArticle

1 Citation (Scopus)
Original languageEnglish (US)
Pages (from-to)1771
Number of pages1
JournalJournal of Rheumatology
Volume40
Issue number10
DOIs
StatePublished - Oct 2013

Fingerprint

Hydroxychloroquine
Antiphospholipid Antibodies
Antirheumatic Agents
Antiphospholipid Syndrome
Systemic Lupus Erythematosus

ASJC Scopus subject areas

  • Rheumatology
  • Immunology
  • Immunology and Allergy

Cite this

Commentary on "the risky business of studying prognosis". / Broder, Anna R.; Putterman, Chaim.

In: Journal of Rheumatology, Vol. 40, No. 10, 10.2013, p. 1771.

Research output: Contribution to journalArticle

@article{e89f9019cf014fff81de1d33379db9c3,
title = "Commentary on {"}the risky business of studying prognosis{"}",
author = "Broder, {Anna R.} and Chaim Putterman",
year = "2013",
month = "10",
doi = "10.3899/jrheum.130393",
language = "English (US)",
volume = "40",
pages = "1771",
journal = "Journal of Rheumatology",
issn = "0315-162X",
publisher = "Journal of Rheumatology",
number = "10",

}

TY - JOUR

T1 - Commentary on "the risky business of studying prognosis"

AU - Broder, Anna R.

AU - Putterman, Chaim

PY - 2013/10

Y1 - 2013/10

UR - http://www.scopus.com/inward/record.url?scp=84885108175&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84885108175&partnerID=8YFLogxK

U2 - 10.3899/jrheum.130393

DO - 10.3899/jrheum.130393

M3 - Article

VL - 40

SP - 1771

JO - Journal of Rheumatology

JF - Journal of Rheumatology

SN - 0315-162X

IS - 10

ER -